Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Scrip Awards 2019 Categories
Entry Deadline: 7 June.
Sponsors
Remember the deadline for entries is 7 June 2019.
Scrip’s Best Company in an Emerging Market Award seeks to reward the growing R&D-based pharmaceutical industry founded in areas beyond its traditional geographic borders of North America, Western Europe and Japan.
This Award is open to any research-based pharmaceutical or biotechnology company that has its headquarters in an emerging market.
The judges will be looking for excellent performance across a range of business activities between June 1, 2018 and May 31, 2019. This could mean anything from growing sales and profits to launching new products, or signing a transformative new deal.
Companies eligible for this Award are those based in emerging markets in Asia, central and eastern Europe, central and south America, the Middle East and Africa.
To enter this category, please answer the following:
The Scrip Award for Best Technological Development in Clinical Trials recognize the promising and disruptive role that digital health technology now plays in clinical drug development. The award applauds advances that are focused on helping sponsors, and those designed to ease the experience of clinical trial participants.
This Award recognizes the vital importance of using the most sophisticated platforms to catalyze and optimize data gathered during clinical trials. Advances in software and applications have a pivotal role to play at all stages of the trial process, assisting sponsors in effective management of study logistics, monitoring, risk mitigation and timely data collection and analysis. The judges will be looking for the product or suite of products that help study teams better manage and oversee clinical trial activities.
All technologies launched or significantly updated between June 1, 2018 and May 31, 2019 are eligible to enter
Companies wishing to enter must have played a role in the development of the nominated technology, and all parties to any joint development agreements should be disclosed in the application.
To enter this category, please provide the following:
This Scrip Award is designed to acknowledge the numerous ways in which pharma and biotech companies give back to the wider community. This could include outreach within a local community, with a charity or patient advocacy group, or alongside an NGO or humanitarian organization.
The judges will be looking for effective partnership activity that took place between June 1, 2018 and May 31, 2019 to the benefit of humankind. Types of partnerships could include, for example, patient and carer support programs, educational programs or disease awareness campaigns or even a social media campaign that went viral.
To enter this category, please answer the following:
This new category will acknowledge and celebrate the outstanding scientific or technological breakthrough that the judging panel believes has the potential to be transformative in the discovery or development of new medicines.
The award is open to any person, group or company that has achieved a genuinely ground-breaking advance during the qualifying period of 1 June 2018 to 31 May 2019. We welcome entries that are active in the life sciences ecosystem – from early-stage research through to clinical proof-of-concept developments.
Achievements we wish to recognize include: insights that advance our understanding of disease biology; new therapeutic targets or approaches; elucidation of a novel mechanism of action; clinical proof of concept of a novel mechanism or novel target; and techniques and technology platforms that enhance the medical benefits of new or existing medicines.
Entries will be judged on the answers to a number of key questions:
This Scrip Award seeks to recognize success in a clinical trial of a new drug product that is expected to lead to an advance in healthcare. This might include the first demonstration of a clear clinical effect for a new drug in an area of unmet medical need, a pivotal study of a new drug with a breakthrough mechanism of action, or a major study of a potential new or expanded indication for an already marketed product.
Unlike the Best New Drug Award, the product involved need not yet be approved, but as with that award the judges will be looking for innovation, clear proof of benefit and potential commercial reward.
To be eligible, the study in question must have been presented for peer review at a major medical meeting or been published in a scientific journal between June 1, 2018 and May 31, 2019.
Entrants must have played a role in the clinical study, and all joint parties must be disclosed in the application.
To enter this category, please answer the following questions:
This Scrip Award seeks to reward successful and creative fundraising by pharma and biotech companies. The investment can come in a variety of guises from grants and public-private partnership deals to venture fundraising and public offerings, but should be earmarked for use in drug discovery and/or development.
In making their decision, the judges will scrutinize entrants on their fundraising strategy, amount raised, the structure of the deal, and on how the money will be used. This Award is open only to companies actually raising the funds (i.e., not bankers or agents). To be eligible, all financing must have been announced between June 1, 2018 and May 31, 2019.
To enter this category, please answer the following questions:
Licensing is vital both in helping to keep pharma’s pipelines replenished and in generating income for smaller firms. Deals considered here are those that involve the licensing of a particular drug, project or group of drugs/projects from one company to another for further development and/ or marketing. (NB It does not include more involved partnerships between companies to explore particular therapeutic strategies (see criteria for the Best Partnership Alliance Award).)
In choosing the winner of Scrip’s Licensing Deal of the Year Award, the judges will look at all aspects of the submitted transactions, from their monetary and strategic value, to the benefits they give to both sides. To qualify, licensing deals must have been closed between June 1, 2018 and May 31, 2019.
To enter this category, please answer the following:
IMPORTANT NOTE Would your entry fit better in the Best Partnership Alliance category? Please consider before you enter.
Scrip’s Best Partnership Alliance Award recognizes the importance of pharmaceutical and/or biotech companies working together to develop new medicines. This category seeks to reward innovative partnerships between companies in which they share the risks and rewards inherent in developing new drugs from the earliest stages.
The judges will be focusing on deals that require strong strategic input from both partners, involving business development, joint marketing/promotion or joint R&D. They are looking for those deals that are the most mutually beneficial, have the most strategic potential, and are innovative in their structure.
Partnerships must have been announced, or have achieved a significant milestone, between June 1, 2018 and May 31, 2019 and entrants should be able to show some sustained benefits from the deal. NB: Deals between majority or wholly owned subsidiaries and their parent companies are not eligible for this Award.
To enter this category, please answer the following:
IMPORTANT NOTE Would your deal fit better into the Licensing Deal of the Year category? Please check before you enter.
Scrip’s Business Development Team of the Year Award will honor the achievements of business development teams whether they are from a pharma or biotech company or a cross-company team responsible for a specific deal or collaborative project.
This Award will go to a team that is truly much more than the sum of its parts. The judges will be looking for strong performance across a number of criteria, such as achievement of short and long-term goals, and good communication of a shared vision.
To enter this category, please answer the following:
Scrip’s Executive of the Year Award is designed to acknowledge excellence in the leadership of large and small pharmaceutical and biotechnology companies. This year’s winner will be the executive who has exhibited exemplary leadership throughout 12 months from June 1, 2018 to May 31, 2019.
This could range from leading an emerging company to an established place within the industry, to turning around the fortunes of a failing company or unit, or leading a firm successfully through the turbulence of a merger or acquisition. Also important to the judges will be the executive’s career achievements, influence within the industry and leadership qualities.
To be eligible for this year’s Award, entrants must hold a C-suite executive position. Candidates must be employed by the company at the time of nomination.
To enter this category, please answer the following:
The Scrip Awards for Best Contract Research Organization acknowledge the critical role that CROs play in drug development. Clinical outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials.
This Award is split into two categories to separate the full-service providers from those smaller CROs that provide specialist services to their clients.
Today, the role of the CRO has gone beyond the traditional model of service-level agreements to offer bespoke clinical trial strategies and CROs are increasingly engaged in risk-sharing partnerships or acting as a single-source developer while also remaining committed to core strengths.
This Award for those companies who provide the full range of services to their clients will be judged on the quality of services and relationships they have built with their clients. It will pay particular attention to the innovative patient recruitment strategies the CRO has brought to the deal.
To qualify, candidates must draw on their achievements in the year between June 1, 2018 and May 31, 2019.
To enter this category, please answer the following:
The Scrip Awards for Best Contract Research Organization acknowledge the critical role that CROs play in drug development. Clinical outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials.
This Award is split into two categories to separate the full-service providers from those smaller CROs that provide specialists services to their clients.
This Award for those companies who provide specialist services to their clients will be judged on the quality of services and relationships they have built with their clients.
To qualify, candidates must draw on their achievements in the year between June 1, 2018 and May 31, 2019.
To enter this category, please answer the following:
The biotech industry’s entrepreneurial spirit and cutting-edge science are vital to the lifesciences industry and the research and development of medicines in the past few decades. This award honors outstanding achievement by biotech companies over the qualifying 12 months.
The winner of the Biotech Company of the Year Award will be the biotech firm that has achieved the most in the 12 months between June 1, 2018 and May 31, 2019. This could be in terms of moving the business from an early stage to a more mature company, signing a transformative deal, taking its first or a major new product towards the market, or raising significant new funds.
To enter this category, please answer the following:
The Best New Drug Award recognizes excellence in pharmaceutical development. Launching innovative new products is the most important function of the industry, and a successful new drug launch marks the culmination of years of risky and expensive R&D.
In this category, the judges will be looking for the small-molecule or biological product that was approved in its first market worldwide during the qualifying period that represents the best therapeutic advance in its area.
All recently launched new active substances, including small-molecules, biologicals or vaccines, are eligible to enter as long as they were first licensed in any market between June 1, 2018 and May 31, 2019. Generic and biosimilar products are not eligible for this award.
Entrants must have played a role in the development of the nominated product, and all parties to joint ventures should be disclosed in the application.
To enter this category, please answer the following:
Scrip’s Pharma Company of the Year Award honors outstanding achievement by pharmaceutical companies over the qualifying 12 months, June 1, 2018 and May 31, 2019. This special award is chosen by Scrip's senior editorial team, based on a variety of key metrics:
The winner of this Award will be an exceptional individual with a consistent history of service, above and beyond the call of duty, throughout their career.
This prestigious international Award will go to someone who has had a distinguished career in the biotech or pharmaceutical arena, primarily within industry. We welcome nominees for consideration for this award but the decision lies with Scrip's senior editorial team. The winner may be retired or semi-retired but will still be active in the industry in some capacity.
Any nomination should outline in no more than 750 words what the nominee has accomplished during his or her career and say why they are worthy of this Award.
All nominations must include:
